News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Investor Alerts Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard September 18, 2024 Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis September 4, 2024 Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome August 28, 2024 Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September August 8, 2024 Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update August 1, 2024 Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update July 24, 2024 Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona Skerjanec July 9, 2024 Immunic Appoints Jason Tardio as Chief Operating Officer and President May 28, 2024 Immunic to Participate in Industry and Scientific Conferences in June May 8, 2024 Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update May 6, 2024 Immunic to Participate in Investor and Scientific Conferences in May Show 5102550100 per page«123456789…19»